AFFILIATIONS
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
6 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
7 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
8 Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China, Shanghai YaKe Biotechnology Ltd., Shanghai, China
9 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
10 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, Institute of Hematology, Zhejiang University, Hangzhou, China, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
ABSTRACT
Background
Epstein-Barr virus (EBV) reactivation remains a clinically important complication in patients with hematologic malignancies. Preliminary findings from our initial analysis suggested that CD19 and BCMA chimeric antigen receptor-T (CAR-T) could induce durable EBV control (Shuyang Wang et al., ASH abstract abs25-10039). Here we present an updated analysis with an expanded patient cohort, extended follow-up, and additional mechanistic analysis to further characterize the durability and immunological basis of EBV control.
Methods
We conducted an updated analysis of patients with B-cell-derived malignancies who received CD19 or BCMA CAR-T across seven clinical trials at our institution. Compared with our previous report, the current analysis included patients from two additional clinical trials. We also comprehensively reviewed pretreatment EBV-DNA assessments obtained during CAR-T eligibility evaluation, allowing inclusion of additional patients with documented baseline EBV positivity whose baseline assessments fell outside the original 7-day window before lymphodepleting chemotherapy. Longitudinal EBV-DNA measurements were analyzed to assess the durability of EBV clearance. Baseline peripheral blood mononuclear cell samples from available patients were sorted into T-, B-, and NK-cell subsets for subsequent EBV-DNA quantification. Post-CAR-T circulating B-cell frequencies were evaluated by flow cytometry. Paired single-cell RNA sequencing (scRNA-seq) and T-cell receptor (TCR) sequencing were performed in five patients before and after CAR-T therapy to characterize changes in endogenous EBV-specific immunity.
Results
Compared with our previous report of 20 patients, the updated cohort included 24 patients with detectable EBV-DNA at baseline, including 17 in CD19 CAR-T cohort and 7 in BCMA CAR-T cohort, and 23 (95.8%) achieved EBV clearance after CAR-T infusion. Among responders, the median time to first documented EBV-negative result was 6 days (IQR, 4.5-17 days) and the median duration of documented EBV-negativity was 507 days (IQR, 284-718 days) at a median follow-up of 22.4 months (IQR, 16.7-29.1 months). The only patient without EBV clearance failed to show measurable expansion of infused CAR-T cells and remained EBV-positive during 1,850 days of follow-up. Three patients developed a subsequent EBV reactivation: one after hematopoietic stem-cell transplantation and two with disease relapse; one patient who received an additional CAR-T regained EBV clearance.
Baseline lymphocyte subsets were sorted in 19 patients. EBV-DNA was quantifiable in at least one subset in nine patients, and five patients had quantifiable EBV-DNA in both T- and B-cells, including one with detection in all three subsets. Among the 9 patients with quantifiable EBV-DNA, the highest EBV-DNA level was observed in B-cells in 6, T-cells in 2, and NK-cells in 1. Measurements of post-CAR-T B-cell frequencies were available in 12 patients in CD19 CAR-T cohort and 6 patients in BCMA CAR-T cohort. Given the persistence of circulating B cells in patients after BCMA CAR-T (BCMA, 3.31% vs. CD19, 0.054%, p=0.025) and detectable EBV-DNA in cross-lymphocyte subsets, B-cell depletion is unlikely to explain durable EBV clearance on its own.
In paired scRNA-seq, EBV-specific T-cells were detected in four patients before CAR-T and in all five patients after. The frequency of EBV-specific T-cells in total T-cells increased following CAR-T therapy, though not statistically significant (median, 0.86% vs. 1.44%, p=0.313). Nevertheless, EBV-specific TCRs showed compositional remodeling, including contraction of dominant pre-CAR-T clonotypes and selective expansion of several other clonotypes. EBV-specific T-cells also showed a stronger antiviral profile (high IRF7/MX1) than other T-cells, and upregulated proliferation pathways compared to pre-CAR-T EBV-specific cells.
Conclusion
This updated analysis further suggested that CD19 and BCMA CAR-T were associated with rapid and durable EBV clearance in patients with B-cell-derived hematologic malignancies. Durable viral control despite circulating B cells or non-B-cell EBV reservoirs points to mechanisms beyond direct B-cell depletion. These updated findings showed that remodeling of endogenous EBV-specific immunity may act as a potential mechanism.